0001126234-19-000026 Sample Contracts

AMENDMENT NO. 1 TO THE AMENDED AND RESTATED LICENSE AGREEMENT FOR RECOMBINANT VESICULAR STOMATITIS VIRUS VACCINES FOR VIRAL HEMORRHAGIC FEVERS

License Agreement • March 5th, 2019 • Newlink Genetics Corp • Pharmaceutical preparations

• Contract Type
  License Agreement
• Filed
  March 5th, 2019
• Company
  Newlink Genetics Corp
• Industry
  Pharmaceutical preparations

WHEREAS Canada and the Company are party to that certain “Amended and Restated License Agreement for Recombinant Vesicular Stomatitis Virus Vaccines for Viral Hemorrhagic Fevers” dated December 5, 2017 (hereinafter the “License Agreement”);

AMENDMENT 4 TO LICENSE AND COLLABORATION AGREEMENT

License and Collaboration Agreement • March 5th, 2019 • Newlink Genetics Corp • Pharmaceutical preparations • New York

• Contract Type
  License and Collaboration Agreement
• Filed
  March 5th, 2019
• Company
  Newlink Genetics Corp
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This fourth Amendment (this “Amendment 4”) is effective as of the last date of signature (the “Amendment Effective Date”), and is entered into by and between MERCK SHARP & DOHME CORP., a corporation organized and existing under the laws of New Jersey (“Merck”), and BIOPROTECTION SYSTEMS CORPORATION, a corporation organized and existing under the laws of Delaware (“NewLink”) and a wholly owned subsidiary of NEWLINK GENETICS CORPORATION, a corporation organized and existing under the laws of Delaware (“NL”).